Targeting Plasmodium PI(4)K to eliminate malaria

Area of Science:

• Malariology
• Medicinal Chemistry
• Parasitology

Background:

• Malaria elimination requires targeting Plasmodium parasites across all life stages.
• Identifying novel drug targets is crucial for developing effective antimalarial therapies.

Purpose of the Study:

• To identify the molecular target of imidazopyrazines, a new class of antimalarial compounds.
• To evaluate the efficacy of imidazopyrazines against various Plasmodium life stages and species.

Main Methods:

• Biochemical assays to identify the target of imidazopyrazines.
• In vitro and in vivo testing in rodent and primate malaria models.
• Assessment of activity against field isolates of Plasmodium falciparum and Plasmodium vivax.

Main Results:

• Phosphatidylinositol-4-OH kinase (PI(4)K) was identified as the target of imidazopyrazines.
• Imidazopyrazines inhibit Plasmodium development across all life stages, including blood, liver, and transmission stages.
• The compounds demonstrated potent preventive, therapeutic, and transmission-blocking activity in preclinical models.
• Activity was confirmed against P. falciparum and P. vivax blood-stage isolates and P. cynomolgi liver-stage hypnozoites.

Conclusions:

• PI(4)K is a critical vulnerability in Plasmodium parasites.
• Imidazopyrazines represent a promising new class of antimalarials targeting PI(4)K.
• This discovery opens new avenues for target-based drug discovery for malaria prevention, treatment, and elimination.